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Abstract 
Preclinical data  shows that intravesical instillation of Ty21a/Vivotif®, a commercial vaccine 
against typhoid fever, is an effective alternative option to standard Bacillus-Calmette-Guérin 
(BCG) immunotherapy for nonmuscle-invasive bladder cancer (NMIBC). Here we 
characterized the inflammatory effects of Ty21a on the bladder and investigated the immune 
mechanisms underlying tumor-regression towards the use of this bacterial vaccine in NMIBC 
patients.  MB49 bladder tumor–bearing mice had significantly improved survival after 
intravesical instillations of Ty21a doses of 10
6
 to 10
8
 colony-forming units. By 
immunohistochemistry and morphology, both BCG and Ty21a instillations were associated 
with bladder inflammation, which was decreased with the use of low, but ,effective doses of 
Ty21a. Flow cytometry analysis showed a significant infiltration of T cells, natural killer 
(NK) cells, and myeloid cells, compared with controls, after a single dose of Ty21a, whereas 
this was only observed after multiple doses of BCG. The induced myeloid cells were 
predominantly neutrophils and Ly6C
+
CD103
+
 dendritic cells (DC), the latter being 
significantly more numerous after instillation of Ty21a than BCG. Ex vivo infection of human 
leukocytes with Ty21a, but not BCG, similarly significantly increased DC frequency. CD4
+
 
and CD8
+
 T cells,  but not NK cells nor neutrophils, were required for effective bladder tumor 
regression upon Ty21a treatment. Thus, the generation of antitumor adaptive immunity was 
identified as a key process underlying Ty21a-mediated treatment efficacy. Altogether, these 
results demonstrate mechanisms behind intravesical Ty21a therapy and suggest its potential as 
a safe and effective treatment for NMIBC patients. 
 
Abstract word count = 250 
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Introduction 
Bladder cancer is the fourth and eighth most common malignancy among men and women, 
respectively (1, 2). Approximately 75% of bladder cancers are diagnosed as non-muscle-
invasive (3) and according to specific tumor stage and grade characteristics, intravesical 
immunotherapy with Bacillus-Calmette-Guerin (BCG) is used to prevent recurrence and/or 
progression (4). However, BCG immunotherapy is associated with significant adverse events, 
mainly bladder irritation, general malaise, and fever, but also severe though rare 
complications (5). In addition, treatment failure may occur in 30-40% of cases (6), hence the 
necessity for alternatives. Along this line, we reported that the attenuated Salmonella enterica 
serovar Typhi Ty21a live vaccine-strain against typhoid fever was effective at inducing 
regression of established bladder tumors using the immunocompetent orthotopic MB49 
bladder-cancer model (7), which closely mimic non-muscle invasive bladder cancer (NMIBC) 
in mice (8). Beside the excellent safety profile of the oral Ty21a vaccine Vivotif®, as 
confirmed worldwide in more than 200 million vaccinees over the last 30 years (9), the 
absence of bacterial survival in the bladder (7) points to it as a viable candidate to test in 
NMIBC patients. Towards this goal, it is crucial to examine whether the local adverse events 
associated to BCG may also be induced by intravesical Ty21a. Here we characterized the 
inflammatory effects of Ty21a on the bladder, but also investigated the innate and/or adaptive 
immune mechanisms underlying tumor-regression in the MB49 bladder-cancer model. Using 
morphology, immunohistochemistry, and flow cytometry, we comparatively characterized 
inflammation and immune cell infiltration in the bladder upon the different intravesical 
treatments and functionally determined key effector cells. Altogether, we highlighted 
mechanisms of intravesical Ty21a therapy that may have potential for safe and efficient 
implementation in NMIBC patients. 
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Material and methods 
Mouse cells 
 The MB49 cell line, derived from a carcinogen induced urothelial carcinoma in male 
C57Bl/6 mice in 1979 (8), was kindly provided in 2009 by Prof. A. Loskog, Uppsala 
University, Sweden), amplified for 1 week (2 passages) and aliquots frozen. Luciferase-
expressing (MB49-luc) and green fluorescent protein (GFP)-expressing (MB49-GFP) cells 
were generated by transfection with lentiviral vectors encoding for firefly luciferase and GFP, 
respectively (kindly provided by Prof. D. Trono, EPFL, Lausanne, Switzerland) of one MB49 
aliquot after 1 passage. MB49-luc and MB49gfp were amplified during 1 week (2 passages), 
tested as free of mycoplasm and aliquots frozen. Further amplifications (2 passages) from the 
initial stock were performed in 2012 and 2018 to generate new aliquots. In all experiment a 
new aliquot of cells is used within 10 days after thawing.  
The MB49 orthotopic bladder tumor model  
Seven to ten-week-old female C57Bl/6 wild type mice (Charles River) were used and all 
experiments were performed in accordance with Swiss law and with approval of the Cantonal 
Veterinary Office of Canton de Vaud, Switzerland. Bladder tumors were established in deeply 
anesthetized mice that were urethrally catheterized using Introcan 24Gx3/4 catheters (Braun, 
Melsungen, Germany). A 15-minute pretreatment with 100 l 22% ethanol was performed 
before instillation of 500,000 MB49-luc (or MB49-GFP) cells in a volume of 50 l. MB49-
luc tumor growth was monitored by bioluminescence 15 minutes after intraperitoneal (ip) 
injection of D-luciferin (Promega, L8220, 150 μg/g of body weight) in the Xenogen imaging 
system (Xenogen/IVIS Caliper Life Science, kindly provided by cellular imaging facility, 
CIF/ UNIL, Lausanne, Switzerland). 100% of the mice will develop bladder tumors. 
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Bioluminescence monitoring of MB49-luc tumors is very efficient for assessing tumor 
establishment and growth during the first 3 weeks; however, uncontrolled loss of 
luminescence of the growing tumors can then often appear (10), requiring additional 
monitoring by palpation, hematuria, and overall health status of the mice, which were 
euthanized  if they reached > 15% weight-loss.  
Ty21a and BCG bacteria preparation 
Ty21a bacteria were prepared by resuspension of the lyophilized content of a Vivotif ® 
capsule (PaxVax, Bern, Switzerland) into 750 l of PBS, resulting in ca.  3 x 109 CFU/ml. 
BCG bacteria were prepared by resuspension of one vial of oncoTICE™ (Essex Chemie SA, 
Luzern, Switzerland) in 1ml of PBS, resulting in ca. 3x 10
8
 CFU/ml. Further dilutions were 
made in PBS as required to achieve the indicated bacteria numbers used in the experiments. 
Intravesical treatments 
Bacterial suspensions (50 l) were instilled by urethral catheterization, as described above. 
The retention time in the bladder was ca 1 hour, until the mice awaken from the anesthesia 
and will spontaneously urinate. Classical treatment (Table 1) starts 1 day after intravesical 
tumor-cell instillation and is administered 4 times at weekly intervals (days 2, 9, 16, and 23). 
In a more stringent setting, a single intravesical treatment–instillation was administered at day 
2 (24 hours after intravesical tumor cell–instillation). Tumors can be detected by 
bioluminescence at day 5, and grow until days 9 to 12 at a similar rate, irrespective of 
instillation with PBS versus BCG or Ty21a.    
Morphology and Immunohistochemistry  
Three m paraffin embedded Hematoxilin-eosin stained sections were used for morphological 
evaluation of bladder specimens, including the urothelial mucosa, muscular, subserosa, and 
serosa layers. The inflammation was evaluated using an inflammatory scoring system as 
previously reported (11).  Score 0: absence or minimal inflammation or epithelial changes. 
Research. 
on February 25, 2019. © 2019 American Association for Cancercancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on January 29, 2019; DOI: 10.1158/2326-6066.CIR-18-0671 
Domingos-Pereira et al., Cancer Immunology Research                 6 
 
Score 1: mild inflammation within the lamina propria accompanied by mild chronic edema, 
hemorrhage, or urothelial changes, zonal fibrosis in lamina propria. Score 2: moderate 
inflammatory infiltrate in the lamina propria and focal extension of the inflammation into the 
muscularis propria, accompanied by moderate edema, hemorrhage, urothelial changes, and 
diffuse fibrosis in the lamina propria. Score 3: severe inflammation in the lamina propria and 
muscularis propria in association with other significant findings including urothelial 
ulceration, severe chronic edema, hemorrhage, and diffuse fibrosis. For 
immunohistochemistry evaluation, paraffin sections of bladders were immunostained using 
the following primary antibodies: CD11b (Abcam ab133357), F4/80 (Caltag MF48000), and 
CD3 (Abcam ab5690), an avidin-biotinylated horseradish peroxidase complex (Vectastain 
Elite ABC Kit), and counterstained with hemalun.  
Immunostaining and flow cytometry analysis 
Mice were sacrificed by CO2 inhalation to collect the bladders. Single-cell suspensions were 
obtained by mincing in DL-dithiothreitol (Sigma, D9779) and digesting stepwise with 0.5 
mg/ml thermolysin (Sigma, T7902) and 1 mg/ml collagenase/dispase (Roche, 11 097 113 01) 
(12) or by single digestion-step with 1 mg/mL collagenase/dispase and 0.1mg/ml DNAse I 
(Sigma-Aldrich, D2552) with 20% Fetal Calf Serum (Gibco, 10270). Whole blood was 
collected in tubes containing heparin-Na 25000 I.E. (Braun, 1718711) from tail vein. Red 
blood cells were lysed using ammonium-chloride-potassium.  
The recovered cells were stained and analyzed by flow cytometry. The following monoclonal 
antibodies (mAbs) to  mouse proteins were used: CD3-PE (17A2, 100206), CD3-
PerCP/Cy5.5 (17A2, 100218), Ly6G-PE/Cy7 (1A8, 127618), CD11b-APC (M1/70, 101212), 
Ly6C-AF700 (HK1.4, 128024), Ly6C-APC/Cy7 (HK1.4, 128026), NK1.1-AF700 (PK136, 
108730), CD4-AF700 (GK1.5, 100430), CD8-APC/Cy7 (53-6.7, 100714), F4/80-APC-Cy7 
(BM8, 123118), CD103-Pcblue (2E7, 121418) (Biolegend); CD4-eF450 (GK1.5, 48-0041-
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82), CD11c-PE (N418, 48-0041), CD11c-PE-eF610 (N418, 61-0014, CD45-PerCP/Cy5.5 
(30-F11, 45-0451), (eBioscience); CD8-PETXRD (53-6.7, 1550-10) (Southern Biotech). 
Isotypes controls were used for CD11c-PE-eF610 (Harmenia Hamster IgG-PE-ef610 (eBio 
229 Arm, 61-4888-80) from eBioscience) and for F4/80-APC-Cy7 and CD8-APC/Cy7 (Rat 
IgG2a kappa-APC/Cy7 (RTK 2758, 400524) from Biolegend ). FMO was used for CD103-
Pcblue determination. Dead cells were excluded by a live/dead fixable aqua dead cell stain kit 
(L34957, Invitrogen,Thermo Fisher Scientific).Cell acquisition and analysis were performed 
using Gallios Flow Cytometer (Beckman Coulter, Nyon, Switzerland) and FlowJo software 
(Tree Star, Ashland, OR), respectively.  
In vitro infections of human leukocytes for DC analysis 
Peripheral blood from healthy volunteers was obtained through the local Swiss blood bank. 
Fresh peripheral blood mononuclear cells (PBMCs) were purified by density gradient 
centrifugation and cryopreserved. PBMCs were infected with Ty21a or BCG at the indicated 
multiplicity of infection (MOI) for 1.5 h at 37°C. Cells were washed and medium containing 
50 μg/mL Gentamycin was added. Following 24 hours of incubation at 37°C, cells were 
harvested and stained for DC identification by flow cytometry. The following mAbs  to 
human proteins were used: CD11c-BV421 (Bu15, 337225), HLA-DR-PE/Cy7 (L243, 
307616) and CD14-FITC (HCD14, 325604) from BioLegend; CD3-PE/AF610 (7D6, 
MHCD0322), CD19-PE/AF610 (SJ25C1, MHCD1922) and CD56-PE/TexasRed (MEM-188, 
MHCD5617) from Invitrogen. Cells were stained for 20 minutes at 4°C, and an amine 
reactive dye (aqua live/dead stain kit, from Life Technologies, L34957) was used for dead cell 
exclusion according to the manufacturer’s instructions. Fc-Receptor Blocking Reagent 
(Miltenyi Biotec, 130-059-901) was used to increase staining specificity. Sample acquisition 
was performed as described above. 
In vivo immune cell depletion 
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The following mAbs from BioXcell were used for cell depletion: CD8 (2.43, BE 0061), CD4 
(GK1.5, BE 0003), NK1.1 (PK136, BE 0036), Ly6G (1A8, BE 0075), Ly6C (Monts1, BE 
0203), or rat IgG2a (2A3, Roche) or IgG2b (LTF2, BE 0090) as isotype controls. A first ip 
injection of 100 μg (anti-CD8), 200 μg (anti-CD4 or anti-Ly6G), 250 μg (anti-NK1.1), or 400 
g (anti-Ly6C), or isotype controls was given 2 days before tumor-implantation. This was 
followed by ip injections every 3-5 days, for a period of ca. 40 days, using half of the first 
dose (except for anti-CD4 and anti-Ly6C that were injected at full dose). 
Statistics 
Statistical analyses were performed using Prism 7.00 for Windows (GraphPad software). 
Single comparisons were performed using Student t test. Multiple comparisons were 
performed using one-way Anova and Dunnets’s post-test or adjusted log-rank test as indicated 
in the figure legends. 
 
Results  
Dosage range of effective intravesical Ty21a bladder-tumor treatment 
Using the mouse MB49 orthotopic bladder cancer model (13-15) we determined the dosage 
range of efficacy of the intravesical Ty21a and BCG treatments (Table 1). After four 
consecutive instillations (1 week apart, starting 1 day after tumor implantation (16)), Ty21a 
induced a significantly higher mice survival (80-90 %), as compared to control PBS treatment 
using doses ranging from 3x10
6
 to 3x 10
8
 CFU/dose (the maximal dose tested, corresponding 
to 1/10 of the content of the Vivotif® capsule). Similar survival in mice was also obtained 
with BCG at 3x 10
7
 CFU/dose (the maximal dose tested, corresponding to 1/10 of the 
Oncotice® vial), whereas treatment with the lower BCG dose (3x 10
6
 CFU) no longer 
conferred significantly improved survival, compared with controls (Table 1). This shows that 
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multiple intravesical Ty21a instillations can control tumor-growth and increase survival in 
mice with doses as low as 3x 10
6
 CFU.   
 
Characterization of bladder wall inflammation upon intravesical treatments 
Intravesical bladder immunotherapy with BCG or Ty21a is associated with the induction of 
inflammatory cytokines (7, 17). Here, we show a morphological analysis of treated bladders 
to characterize inflammatory features, including the presence of edema, fibrosis, and immune 
cell infiltration, as summarized by an inflammatory score (11) (Fig. 1A). Single intravesical 
instillation with either BCG or Ty21a (3 x 10
7 
CFU) induced significant inflammation in the 
bladder 24 hours later, which was considerably decreased after 7 days (Fig. 1B). Similar 
inflammation was induced 24 hours after the fourth consecutive instillation with either BCG 
or Ty21a; however, inflammation persisted for at least 3 weeks (Fig. 1C). When thelower 
dose (3x 10
6
 CFU) were used, inflammation was still present upon BCG administration, but 
not upon Ty21a treatment. These data show that bladder tissue inflammation can be reduced 
by using low, but still effective (Table 1), doses of Ty21a.  
Characterization of immune cell infiltration in the bladder upon intravesical treatments 
Infiltration of myeloid cells and T cells in the bladder upon Ty21a or BCG instillations was 
evaluated by immunohistochemistry (Fig. 2A and Table 2). Myeloid cells (CD11b
+
), mainly 
of the granulocytic phenotype, were slightly increased within 24 hours following instillation 
of PBS alone and to a greater extent by BCG or Ty21a; however, within 7 days, 
myeloid/granulocytes represented again less than 10% of the bladder area similarly to the 
PBS- treated bladder. In contrast, following multiple BCG instillations (either 3x 10
6
 or 3x 
10
7
 CFU/dose), a strong (10-50 % of the bladder area, Table 2) myeloid/granulocyte 
infiltration was maintained for at least 3 weeks. Macrophages (F4/80
+
) were only consistently 
observed after multiple doses of BCG, whereas T cells (CD3
+
) were increased by Ty21a at 
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early time points (24 hours) and by BCG at later time points (3 weeks). Immune cell 
infiltration was further characterized and quantified by flow-cytometry (Fig. 2B and C, 
Supplementary Fig. S1A). The data show a significant infiltration in the bladder of T cells and 
Natural Killer (NK) cells 24 hours after a single Ty21a instillation, whereas myeloid cells 
were significantly induced by either Ty21a or BCG, as compared to PBS-treated and 
untreated mice (Fig. 2B). A significantly greater number of T cells was maintained for 1 week 
after Ty21a instillation (Fig. 2B, left), whereas NK cells and myeloid cells returned to the 
numbers measured in PBS-instilled or untreated mice (Fig. 2B, middle and right). A 10-fold 
higher dose of Ty21a (3x10
8
 CFU) did not induce greater immune-cell infiltration (Fig. 2B, 
dark green bars). After multiple instillations (Fig. 2C), there was a significant increase in T 
cell, NK, and myeloid cell numbers upon successive BCG instillations as compared to the 
first dose. In contrast, successive Ty21a doses did not further increase the number of myeloid 
cells and only to a lesser extent the number of T cells and NK cells (only significant after the 
third and fourth dose); as compared to the first dose (Fig. 2C). The myeloid cells induced after 
instillation were further phenotyped by flow cytometry (Supplementary Fig. S1B). They 
consisted predominantly of Ly6G
+ 
neutrophils (40-60%), followed by Ly6C
+ 
monocytes (15-
20%), dendritic cells (DCs, 15-30%), and fewer F4/80
+ 
macrophages (3-7%, Table 3), in 
agreement with the immunohistochemical data (Table 2). Although the proportion of 
neutrophils was significantly higher upon BCG administration than upon Ty21a treatment, the 
proportion of DCs was higher upon treatment with Ty21a than with BCG. Further analysis of 
DCs infiltrating the bladder upon instillation of Ty21a or BCG (Fig. 2D and E) showed that 
they were mainly Ly6C
+
CD103
+
CD11c
+
 DCs (Fig. 2D) in both type of intravesical 
instillations, but in significantly higher numbers upon treatment with Ty21a than BCG (Fig. 
2E). These DCs thus shared markers of both inflammatory (Ly6C
+
 (18)) and cross-presenting 
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(CD103
+ 
(19)) DCs. Their presence in the bladder, together with the higher number of T cells 
(Fig 2E), highlight the potential of Ty21a to promote antitumor T-cell responses locally.   
 
In contrast to BCG, Ty21a infection of human PBMC increases dendritic cell frequency  
As a surrogate for comparing the effects of BCG and Ty21a instillations on human bladder 
DC, we examined DC frequency upon ex vivo infection of human peripheral blood 
mononuclear cells (PBMC). Data show that 24 hours after infection, the frequency of DCs 
(LineagenegCD11c+HLA-DRhigh, Fig. 3A) was significantly increased by Ty21a, but not by 
BCG (both at a multiplicity of infection (MOI) = 0.5), as compared to medium alone (Fig. 
3B). A significantly higher frequency of DCs was also obtained with Ty21a when high MOI 
(10) was used. In contrast, infection with BCG at MOI=10 resulted in a significantly 
decreased DC frequency  as compared to medium (Fig. 3B), suggesting a higher toxicity of 
BCG towards myeloid cells (see total CD11c
+
 cell frequency in Supplementary Fig. S2), 
possibly attributed to its greater persistence in PBMC as compared to Ty21a (7). Altogether, 
these data suggest that intravesical Ty21a may also promote DC infiltration in the human 
bladder, in contrast to BCG.  
 
 
Functional characterization of effector cells involvedin Ty21a bladder tumor treatment.  
We examined the presence of DCs in MB49 bladder tumors following intravesical treatments 
performed with BCG or Ty21a 1 day or 5 days after tumor instillation. At both time points, 
significantly higher numbers of CD103
+
Ly6C
+
CD11c
+
 DCs / mg of bladder-tumor were 
obtained 1 day after intravesical Ty21a as compared to BCG (Fig. 4A), similar to the data 
obtained in the absence of tumor (Fig. 2E). To highlight the potential of 
CD103
+
Ly6C
+
CD11c
+
 DCs to present tumor antigen, we used MB49 cells expressing green 
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fluorescent protein (GFP) and examined whether these DCs had engulfed GFP from the 
tumors. Compared  with MB49-luc tumors, ca. 5 % of CD103
+
Ly6C
+
CD11c
+
 DCs were GFP
+
 
at day 6 in MB49-GFP tumors (Fig. 4B). Comparison between intravesical BCG and Ty21a 
treatments in this setting further confirmed that a significantly higher number of 
CD103
+
Ly6C
+
CD11c
+
 GFP
+
 DCs / mg of tumor was obtained after Ty21a than after BCG 
(Fig. 4C). This suggests that CD103
+
Ly6C
+
CD11c
+
  DCs may be key for the Ty21a 
treatment. 
To functionally investigate the immune cells involved in the Ty21a-mediated tumor-
regression, we performed a single Ty21a intravesical instillation (3 x 10
7
 CFU) 1 day after 
MB49 bladder tumor implantation, a treatment protocol that we previously showed to 
significantly increase mice survival (7). This allowed antibody-mediated immune-cell 
depletion to be performed without interfering with successive Ty21a treatments. Depletion of 
CD4
+
 T cells, CD8
+
 T cells, NK cells, and Ly6G
+
 neutrophils was highly effective and 
maintained for more than one month, as detected in the blood (Supplementary Fig. S3A). In 
contrast, our attempt to deplete CD103
+
Ly6C
+
CD11c
+
 DC with a Ly6C-depleting antibody 
only resulted in partial depletion (ca. 50%) of the Ly6C
+ 
myeloid cells in blood 
(Supplementary Fig. S3B) and of the Ly6C
+
CD11c
+
 DCs in the bladder (Supplementary Fig. 
S3C). Tumor luminescence, as a surrogate for tumor volume, was not significantly different 
10 days after tumor implantation in the different treatment groups, whereas 1 week later, 
significantly larger tumors were found in CD4-, CD8-, and Ly6C-depleted Ty21a-treated 
mice compared to mice receiving intravesical Ty21a with isotype control antibodies (Fig. 
4D). In contrast, neutrophil- or NK-depleted Ty21a-treated tumors were similar to those in 
control Ty21a-treated mice, suggesting that neutrophils and NK cells are not necessary for an 
effective Ty21a treatment. Indeed, mouse survival was not affected by the long-term 
depletion of neutrophils and NK cells (35–40 days) after intravesical Ty21a treatment (80–
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90% survival, Fig. 4E). In contrast, CD4
+
 or CD8
+
 T-cell depletion rapidly decreased mouse 
survival, and all mice were euthanized before day 40 (Fig. 4E), demonstrating that these T 
cells were essential immune cells for Ty21a treatment efficacy. The survival of the Ly6C
+
-
depleted group was not significantly affected, with only 2 of10 mice dying at earlier time 
points than the control group (Fig. 4E). This suggests that the partial depletion of 
CD103
+
Ly6C
+
CD11c
+
 DCs was not sufficient for long-term interference with the Ty21a 
treatment. Altogether, these data demonstrate the requirement for T cells (CD4
+
 and CD8
+
) 
and suggest the importance of CD103
+
Ly6C
+
CD11c
+
 DCs for the intravesical Ty21a 
treatment of bladder tumors, whereas, in contrast to BCG(17), neutrophils and NK cells are 
not necessary.  
 
 
 
 
 
 
 
 
 
 
DISCUSSION    
Our data show that significantly improved survival of MB49 bladder tumor–bearing mice 
could be achieved by intravesical instillations of Ty21a at doses that induce only low 
inflammation in the bladder. With a single instillation, Ty21a induced significant infiltration 
of T cells and DCs in the bladder at numbers that required multiple instillations with BCG. In 
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contrast to BCG, for which mechanisms of action involve induction of both innate (mainly 
neutrophils and NK cells) and adaptive immune responses (17), the therapeutic effect of 
Ty21a relied on the presence of T cells and DC, but not of neutrophils and NK cells.  
Our results also indicate that a particular type of DC expressing Ly6C, CD11c, and CD103 
infiltrated the bladder and the MB49 bladder tumor upon Ty21a or BCG instillation. Ty21a 
instillation induced ca. 4-fold more of these DCs in the bladder than BCG.  Similar Ly6C
+
 
DCs were reported to differentiate from monocytic precursors upon inflammatory signals 
activating p53 within tumors undergoing immunogenic chemotherapies (20). Whether Ty21a 
may use a similar process to promote such an immunogenic microenvironment within the 
treated tumor deserves further investigation. Experiments with human PBMC further 
confirmed an increased DC frequency upon Ty21a infection, in contrast to BCG. In the 
context of anti-tuberculosis vaccines, the relatively poor immunogenicity of BCG was 
previously associated with DC impairments, such as a poor maturation capacity (21, 22). The 
presence of DCs able to efficiently cross-present tumor antigen for activating antitumor T-cell 
immunity is crucial for an effective immunotherapy (23). In the absence of a specific tumor 
antigen, we could not assess the cross-presenting potential of the Ly6C
+
CD11c
+
CD103
+
 DCs 
but demonstrated their ability to engulf tumor antigen (GFP). It was previously reported that 
Salmonella enterica serovar Typhi can induce maturation of human DC capable of cross-
presenting bacterial antigen and priming Typhi-specific CD8
+
 T cells (24). Given that Ty21a 
can rapidly induce urothelial tumor-cell death (7), this in combination with Ty21a-induced 
DCs may enable efficient cross-presentation of the released tumor antigens and activation of 
antitumor T cells either locally and/or in the draining lymph nodes.  This process may explain 
why a single intravesical instillation of Ty21a is more efficient than BCG to induce regression 
of established bladder tumors and improve survival of treated mice (7). 
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Here we present a thorough analysis of the inflammatory effects of single and successive 
intravesical instillations of BCG on morphology and immune infiltration in the bladder of 
mice. Our analysis is in line with previously-reported data from NMIBC patients undergoing 
intravesical BCG immunotherapy, which resulted in augmented immune responses, including 
increased cytokine concentrations and immune cells in the urine upon successive BCG 
instillations (25-27). In contrast, a single Ty21a instillation was sufficient to induce DCs and 
T cells capable of controlling tumor growth. Successive instillation of Ty21a, compared with 
BCG, did not result in a similar profile of enhanced innate immune cell infiltration and 
inflammation of the mouse bladder, particularly when the lower doses were used. Repeated 
exposure to lipopolysaccharide of gram negative bacteria was shown to transiently silence 
inflammatory cytokines to prevent excessive inflammation(28, 29), which may partly explain 
our finding.  
Immunotherapy of NMIBC with BCG is multifactorial, relies on an intact immune system, as 
the inflammatory response is crucial, with neutrophils playing a primary role (14). This overt 
inflammation, however, often leads to adverse events that can greatly reduce the patient’s 
compliance. Although attempts to reduce the dose of BCG to one third (30) or one half (31) 
resulted in decreased toxicity, full efficacy could not be guaranteed, and the standard BCG 
regimen is still recommended (32).  
The finding that Ty21a-mediated immunotherapy can operate in the absence of NK cells, 
neutrophils, and overt inflammation therefore holds promise for the implementation of this 
type of intravesical treatment in NMBIC patients, and a phase I trial is currently recruiting 
patients in our hospital (NCT 03421236: IVES Ty21a). 
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Table 1 Dose-dependent efficacy of intravesical treatments of MB49 bladder 
tumors bearing mice 
Treatmentsa Surviving mice 
at day 70 (%) 
Number of alive 
mice/initial total 
number 
P valuesb 
Ty21a 3x 108 CFUc 80 16/20 0.0076  
Ty21a 3x 107 CFU 85 17/20 0.0023  
Ty21a 3x 106 CFU 90 9/10 0.0060  
BCG 3x 107 CFU 80 16/20 0.0076  
BCG 3x 106 CFU 70 7/10 0.1141 
PBS    33.3 6/18 NAd 
a Treatments were instilled 1, 8 ,15 and 22 days after tumor implantation 
b P values after comparison to PBS treatment following a Fisher’s exact test 
c CFU: colony forming unit 
d NA: not applicable 
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Table 2 Immunohistochemial evaluation of immune infiltration in the bladder 
upon intravesical instillations.  
 
a myeloid cells included mainly granulocytic cells 
b NA: not applicable 
c area of 2mm2 were examined and reported score is a median value of all counted 
cases: +: 1-5% of bladder area, ++: 5-10% of bladder area, +++ 10-50% of bladder 
area,++++ >50% of bladder area, 0= none observed 
d intravesical instillations were performed at days 1, 8 ,15 and 22  
 
Intravesical instillations Time post 
last 
instillation 
Cd11b+ 
myeloid 
cellsa 
F4/80+ 
macrophages 
CD3+ 
T-cells   
none NAb +c 0 + 
1 x PBS 24h ++ 0 + 
1 week ++ + + 
1 x Ty21a 3x 107 CFU 24h ++++ + +/++ 
1 week ++ 0 + 
1 x BCG 3x 107 CFU 24h +++ 0 + 
1 week ++ + + 
 
4d x PBS 24h ++ + + 
1 week ++ 0 + 
3 weeks + 0 + 
4 x Ty21a 3x 107 CFU 24h ++++ + ++ 
1 week +++ 0 + 
3 weeks ++ + ++ 
4 x BCG 3x 107 CFU 24h +++ + + 
1 week +++ + + 
3 weeks +++ + +++ 
4 x Ty21a 3x 106 CFU 24h +++ + + 
1 week ++ + + 
3 weeks ++ 0 + 
4 x BCG 3x 106 CFU 
 
24h +++ + + 
1 week ++ + + 
3 weeks +++ + +/++ 
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Table 3 Proportion of different immune cell subtypes among myeloid cells upon 
intravesical instillation 
 
 Neutrophila  
(Ly6G+) 
Monocytesa  
(Ly6C+ CD11c–)      
Macrophagesa  
(F4/80+ Ly6C–CD11c–) 
DCa  
(CD11c+)   
Naïve b   3.4 ±   1.1   8.4 ± 0.6          11.3 ± 1.7              42.0 ± 3.1 
PBS 40.1 ± 14.4 16.1 ± 4.4              6.5 ± 2.1              22.2 ± 6.7 
BCG 61.9 ±   0.5 15.3 ± 0.2              2.8 ± 0.5              14.9 ± 0.3 
Ty21a 44.1 ±   1.2****c 19.5 ± 1.0              2.7 ± 0.3        26.5 ± 2.1**c 
 
a % among myeloid cells (Mean ±SEM) 24h after intravesical instillations 
b n =  3 mice/each group   
c ****: P < 0.0001 following a One-way Anova and a Sidak’s multiple comparison test of BCG 
against Ty21a 
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Figure legends 
Figure 1: Bladder inflammation upon intravesical Ty21a or BCG instillations   
Hematoxilin-eosine stained, paraffin sections of bladders from mice (n = 3-6) euthanized 1 or 
7 days after a single or four consecutive (once per week) intravesical instillations with PBS, 
BCG (3 x 10
7
 or 3 x 10
6
 CFU), or Ty21a (Ty, 3 x 10
7
 or 3 x 10
6
 CFU), were compared to 
naïve mice using an inflammatory score.  Representative pictures of inflammatory scores of 0, 
1, 2, and 3 are shown in A. Fibrosis (arrowhead), edema (star) and ulceration (arrow) are 
indicated; original magnification was 200x. Means ± SEM of inflammatory scores in the 
groups of mice that received a single intravesical instillation (B) or 4 consecutive instillations 
(C) as indicated below the graphs, are shown. *: p< 0.05, **: P < 0.01 and ***: P < 0.001 
following a one-way ANOVA and a Dunnet’s post-test for comparison to naïve mice. 
 
Figure 2: Immune cell infiltration upon intravesical Ty21a or BCG instillations   
A: Immunohistochemical characterization of the immune infiltrates upon intravesical 
instillations. T cells (CD3
+
, left image), macrophages (F4/80
+
, middle image), and myeloid 
cells (CD11b
+
) including mainly granulocytes (right image) are identified. B and C: Flow 
cytometry analysis of  immune cells recovered from bladders of naïve mice or from mice 
euthanized at the indicated time points after a single intravesical instillation with PBS, BCG 
(3 x 10
7
 CFU), or Ty21a (Ty, 3 x 10
7
 or 3 x 10
8
 CFU, labelled as Ty10x) (B) or 24 hours after 
each successive intravesical instillations (post 1, 2, 3, and 4) (C).  Individual values and mean 
± SEM numbers for CD3
+
 T cells, NK1.1
+
 NK cells and CD11b
+
 myeloid cells are shown. D 
and E: Flow cytometry characterization of DC recovered from bladder 24 hours after BCG 
and Ty21a (Ty, 3x 10
7
 CFU) intravesical instillation. Representative cytometry plots and 
histograms for DCs (Ly6C
+
 CD11c
+
 CD103
+
) and CD3
+
 T cells are shown for each treatment 
in D, and comparative analysis of myeloid and T cell content (individual values and mean ± 
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SEM) is shown in E.  *: p< 0.05, **: p< 0.01 , ***: p< 0.001   and  ****: p< 0.0001 
following a one-way ANOVA and a Dunnet’s post-test for comparison to naïve and to PBS in 
(B) or to post dose 1 in (C) or following a one way ANOVA multiple comparison and Sidak’s 
post-test between BCG and Ty21a (E).  
 
Figure 3: DC frequency upon Ty21a or BCG infection of human PBMC   
PBMCs were cultured for 24 hours alone or after BCG or Ty21a infection (Ty, MOI=0.5 and 
MOI=10). A: Representative flow cytometry plots showing the gating strategy for the 
identification of dendritic cells (DCs). After gating on live cells, DCs were defined as 
Lineage
neg
CD11c
+
HLA-DR
high
 (with lineage including CD3, CD19, CD56, and 
subsequently, CD14). B: DC frequencies (individual values and mean + SEM) among live 
cells are shown for each indicated conditions. One-way ANOVA for paired values followed 
by Tukey’s post-test for multiple comparison: *p<0.05; ***p<0.001; ****p<0.0001.   
 
Figure 4: Key effector cells involved in intravesical Ty21a bladder tumor treatment  
A: Comparative analysis of CD103
+
Ly6C
+
CD11c
+ 
DC content in bladder
 
tumor instilled with 
BCG or Ty21a (Ty) one day (D1) or 5 days (D5) after MB49 instillation. Individual numbers 
and mean of CD103
+
Ly6C
+
CD11c
+ 
DCs / mg of tumor recovered 1 day after BCG or Ty21a 
(Ty) instillation are indicated. B: representative cytometry plot of GFP
+
 cells among 
CD103
+
Ly6C
+
CD11c
+ 
DCs in MB49-GFP tumors as compared to MB49-luc tumors. C: 
Comparative analysis of CD103
+
Ly6C
+
CD11c
+
GFP
+ 
DC content in bladder
 
tumor instilled 
with BCG or Ty21a 5 days after MB49-GFP instillation. Individual numbers and mean of 
CD103
+
Ly6C
+
CD11c
+
GFP
+ 
DCs / mg of tumor recovered 1 day after BCG or Ty21a (Ty) 
instillation are indicated. Groups in A and C were compared with a Student t test, D and E:  
Groups of mice receiving a single intravesical Ty21a instillation (3 x 10
7
 CFU) 1 day after 
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bladder tumor implantation, as well as depleting antibodies (anti-Ly6C, n = 10; anti-Ly6G, n 
= 8; anti-NK-cells, n = 8; anti-CD4, n = 8; and anti-CD8, n = 8); or an isotype control (n = 
26); were compared. D: Individual and mean (horizontal bars) bladder-tumor 
bioluminescences of the indicated groups of mice at days 10 and 17. E: survival of the 
indicated groups of mice over time. The treatment groups were compared to the isotype group 
with a one-way ANOVA with Dunnett’s post-test (D) or an adjusted log rank test (E). **: P < 
0.01; ****: P < 0.0001  
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